Epsilogen

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies for the treatment of cancer. The company’s lead candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter clinical trials, with encouraging Phase I trial data indicating that MOv18 IgE is safe and well-tolerated, with early signs of clinical activity also observed. The company has also developed a proprietary IGEGTM antibody platform, combining elements from both IgE and IgG antibodies into novel proprietary antibody molecules with enhanced functionality.